MARKET

SESN

SESN

Sesen Bio, Inc.
NASDAQ
0.3893
-0.0017
-0.43%
After Hours: 0.3988 +0.0095 +2.44% 16:17 09/29 EDT
OPEN
0.3900
PREV CLOSE
0.3910
HIGH
0.3970
LOW
0.3800
VOLUME
802.49K
TURNOVER
0
52 WEEK HIGH
1.470
52 WEEK LOW
0.3650
MARKET CAP
77.65M
P/E (TTM)
1.642
1D
5D
1M
3M
1Y
5Y
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers
Benzinga · 09/22 08:04
US Stocks Edge Higher As Fed Raises Interest Rates By 75 Basis Points
U.S. stocks traded slightly higher toward the end of trading session on Wednesday following the announcement of interest rate decision by the Fed.
Benzinga · 09/21 18:41
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 09/21 16:40
S&P 500 Rises 0.5%; Crude Oil Falls Sharply
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.
Benzinga · 09/21 16:28
Carisma Therapeutics to go public through merger with Boston-area biopharm firm
The company has also secured commitments from a syndicate of investors — which include Penn Medicine — for a $30 million financing.
American City Business Journals · 09/21 15:08
Novartis, Moderna Partner Agree To Merge With Beleaguered Sesen Bio
Benzinga · 09/21 14:02
Sesen Bio in merger deal with immunotherapy company Carisma Therapeutics
Cancer-focused biotech Sesen Bio, Inc. (NASDAQ:SESN) announced a merger...
Seekingalpha · 09/21 12:22
Sesen Bio, Carisma Therapeutics Announce Merger Agreement With Clinical-Stage Biotech Company; Combined Co To Have ~$180M Of Cash, Cash Equivalents
Transaction to create a well-funded, clinical-stage biotechnology company advancing engineered macrophages for the treatment of cancer and other serious disorders Combined company expected to have
Benzinga · 09/21 12:13
More
About SESN
Sesen Bio, Inc. is a late-stage clinical company engaged in advancing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).

Webull offers kinds of Sesen Bio Inc stock information, including NASDAQ:SESN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SESN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SESN stock methods without spending real money on the virtual paper trading platform.